MiR-34 - a microRNA replacement therapy is headed to the clinic

572Citations
Citations of this article
362Readers
Mendeley users who have this article in their library.

Abstract

MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic. © 2012 Bader.

Cite

CITATION STYLE

APA

Bader, A. G. (2012). MiR-34 - a microRNA replacement therapy is headed to the clinic. Frontiers in Genetics, 3(JUL). https://doi.org/10.3389/fgene.2012.00120

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free